Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001193125-21-102332 0001388325 XXXXXXXX LIVE 6 Common Stock, par value $0.0001 per share 04/23/2026 false 0001710072 28036F105 Edgewise Therapeutics, Inc. 1715 38th St. Boulder CO 80301 Barbara Fiorini 45 3527 6592 Novo Holdings A/S Tuborg Havnevej 19 Hellerup G7 DK-2900 0001388325 N Novo Holdings A/S WC N G7 5350000.00 0.00 5350000.00 0.00 5350000.00 N 4.9 CO Common Stock, par value $0.0001 per share Edgewise Therapeutics, Inc. 1715 38th St. Boulder CO 80301 This Amendment No. 6 (this "Amendment No. 6" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on March 31, 2021, and amended on September 16, 2022, September 30, 2022, June 28, 2023, January 25, 2024 and September 23, 2024 (as amended, the "Statement") by the Reporting Person. This Amendment No. 6 is being filed to report the dilution of the Reporting Person's beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Person. Unless otherwise defined herein, capitalized terms used in this Amendment No. 6 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. Novo Holdings A/S beneficially owns 5,350,000 shares of common stock representing approximately 4.98% of the Issuer's outstanding shares of common stock, based upon 107,532,173 shares of common stock outstanding as of April 9, 2026, as reported in the Issuer's definitive proxy statement, filed with the SEC on April 23, 2026. Due to field limitations of the EDGAR filing system, the percentage listed in Row 13 of the Reporting Person's cover page has been rounded down to 4.9%. Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares. Novo Holdings A/S has not effected any transactions in the Issuer's common stock within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuer's common stock within the past 60 days. Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares. The Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock on April 23, 2026. Exhibit 99.1 Schedule I Novo Holdings A/S /s/ Barbara Fiorini By Barbara Fiorini, General Counsel, Finance & Operations 04/27/2026